CCC
DGX icon

Crescent Capital Consulting’s Quest Diagnostics DGX Stock Holding History

Crescent Capital Consulting’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$20K Hold
117
– – ﹤0.01% 355
2021
Q3 		$17K Hold
117
– – ﹤0.01% 393
2021
Q2 		$15K Hold
117
– – ﹤0.01% 346
2021
Q1 		$15K Hold
117
– – ﹤0.01% 364
2020
Q4 		$14K Buy
+117
New +$14.3K ﹤0.01% 334

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Crescent Capital Consulting's DGX Position: Q4 2021 in Review

Crescent Capital Consulting held its Quest Diagnostics (DGX) position steady in Q4 2021 at 117 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #355.

Crescent Capital Consulting first reported a position in DGX in Q4 2020 and has held it in 5 quarters since. 905 funds tracked by Wall St. Rank hold DGX as of Q4 2021.

  • Crescent Capital Consulting held 117 shares of Quest Diagnostics worth $20K as of Q4 2021.
  • Crescent Capital Consulting left its Quest Diagnostics share count unchanged in Q4 2021.
  • Quest Diagnostics made up ﹤0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #355 holding.
  • Crescent Capital Consulting first reported a position in Quest Diagnostics in Q4 2020 and has held it in 5 quarters since.
  • 905 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.